6955 Stock Overview
A biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Shandong Boan Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$11.00 |
| 52 Week High | HK$25.00 |
| 52 Week Low | HK$7.51 |
| Beta | 0.023 |
| 1 Month Change | -20.06% |
| 3 Month Change | 27.17% |
| 1 Year Change | 14.23% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6955 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 13.4% | 13.0% | 1.6% |
| 1Y | 14.2% | 64.2% | 14.8% |
Return vs Industry: 6955 underperformed the Hong Kong Biotechs industry which returned 58.4% over the past year.
Return vs Market: 6955 matched the Hong Kong Market which returned 14% over the past year.
Price Volatility
| 6955 volatility | |
|---|---|
| 6955 Average Weekly Movement | 22.3% |
| Biotechs Industry Average Movement | 13.5% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in HK Market | 15.3% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 6955's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6955's weekly volatility has increased from 12% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 760 | Hua Jiang | www.boan-bio.com |
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China and internationally. Its commercialized products include Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, cervical cancer and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of postmenopausal women with osteoporosis; and Boluojia (BA1102), a fully human IgG2 anti-RANKL monoclonal antibody. The company also develops BA5101, a long-acting glucagon-like peptide-1 receptor agonist intended for glycemic control in adults with type 2 diabetes; BA9101, a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection; BA1104, a monoclonal antibody that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 receptor; BA2101, a long-acting human monoclonal antibody of the IgG4 subtype that targets interleukin-4 receptor subunit a in phase 2 clinical trial; BA1106, a non-IL-2 blocking anti-CD25 antibody; BA1202, a novel bi-specific antibody drug that targets CEA/CD3; BA1301, an ADC candidate that targets Claudin 18.2; and BA1302, a novel CD228-directed ADC.
Shandong Boan Biotechnology Co., Ltd. Fundamentals Summary
| 6955 fundamental statistics | |
|---|---|
| Market cap | HK$5.90b |
| Earnings (TTM) | HK$79.55m |
| Revenue (TTM) | HK$789.47m |
Is 6955 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6955 income statement (TTM) | |
|---|---|
| Revenue | CN¥726.32m |
| Cost of Revenue | CN¥183.66m |
| Gross Profit | CN¥542.65m |
| Other Expenses | CN¥469.46m |
| Earnings | CN¥73.19m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 74.71% |
| Net Profit Margin | 10.08% |
| Debt/Equity Ratio | 41.3% |
How did 6955 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 15:07 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shandong Boan Biotechnology Co., Ltd. is covered by 0 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.